Crisdesalazine

Crisdesalazine ( ; developmental code name AAD-2004) is a microsomal prostaglandin E2 synthase-1 (mPGES-1) inhibitor and free radical scavenger which is under development for the treatment of Alzheimer's disease, amyotrophic lateral…

Uses your system voice; voice and rate in settings.

≈ 1 min read

Cite, export and learn8 citation formats · 8 exports · lesson and quiz

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Crisdesalazine ( ; developmental code name AAD-2004) is a microsomal prostaglandin E2 synthase-1 (mPGES-1) inhibitor and free radical scavenger which is under development for the treatment of Alzheimer's disease, amyotrophic lateral sclerosis (ALS), depressive disorders, Parkinson's disease, and spinal muscular atrophy. It was also under development for the treatment of arthritis, diabetes, pain, and pancreatitis, but development for these indications was discontinued.

Crisdesalazine is also approved under the brand name GedaCure for treatment of dogs with canine cognitive dysfunction.

See also

List of investigational antidepressants List of investigational Parkinson's disease drugs Selegiline § Veterinary use

Text derived from https://en.wikipedia.org/w/index.php?oldid=1370137270 under CC BY-SA 4.0; modifications have been made.

Provenance

snapshot enwiki-001370137270 · captured 2026-08-19 · ledger · version history

Cite this page as: encyclopegia.org, “Crisdesalazine”, snapshot enwiki-001370137270. https://encyclopegia.org/a/crisdesalazine

Sources cited in this revision

3 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.